These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 17968022)

  • 1. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.
    Austen B; Skowronska A; Baker C; Powell JE; Gardiner A; Oscier D; Majid A; Dyer M; Siebert R; Taylor AM; Moss PA; Stankovic T
    J Clin Oncol; 2007 Dec; 25(34):5448-57. PubMed ID: 17968022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
    Skowronska A; Parker A; Ahmed G; Oldreive C; Davis Z; Richards S; Dyer M; Matutes E; Gonzalez D; Taylor AM; Moss P; Thomas P; Oscier D; Stankovic T
    J Clin Oncol; 2012 Dec; 30(36):4524-32. PubMed ID: 23091097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele.
    Skowronska A; Austen B; Powell JE; Weston V; Oscier DG; Dyer MJ; Matutes E; Pratt G; Fegan C; Moss P; Taylor MA; Stankovic T
    Haematologica; 2012 Jan; 97(1):142-6. PubMed ID: 21933854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.
    Austen B; Powell JE; Alvi A; Edwards I; Hooper L; Starczynski J; Taylor AM; Fegan C; Moss P; Stankovic T
    Blood; 2005 Nov; 106(9):3175-82. PubMed ID: 16014569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage.
    Britt-Compton B; Lin TT; Ahmed G; Weston V; Jones RE; Fegan C; Oscier DG; Stankovic T; Pepper C; Baird DM
    Leukemia; 2012 Apr; 26(4):826-30. PubMed ID: 21986843
    [No Abstract]   [Full Text] [Related]  

  • 6. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance.
    Cuneo A; Bigoni R; Rigolin GM; Roberti MG; Bardi A; Cavazzini F; Milani R; Minotto C; Tieghi A; Della Porta M; Agostini P; Tammiso E; Negrini M; Castoldi G
    Haematologica; 2002 Jan; 87(1):44-51. PubMed ID: 11801464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia.
    Ouillette P; Li J; Shaknovich R; Li Y; Melnick A; Shedden K; Malek SN
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1125-32. PubMed ID: 22952040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.
    Lin K; Adamson J; Johnson GG; Carter A; Oates M; Wade R; Richards S; Gonzalez D; Matutes E; Dearden C; Oscier DG; Catovsky D; Pettitt AR
    Clin Cancer Res; 2012 Aug; 18(15):4191-200. PubMed ID: 22675167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia.
    Schaffner C; Stilgenbauer S; Rappold GA; Döhner H; Lichter P
    Blood; 1999 Jul; 94(2):748-53. PubMed ID: 10397742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.
    Rose-Zerilli MJ; Forster J; Parker H; Parker A; Rodríguez AE; Chaplin T; Gardiner A; Steele AJ; Collins A; Young BD; Skowronska A; Catovsky D; Stankovic T; Oscier DG; Strefford JC
    Haematologica; 2014 Apr; 99(4):736-42. PubMed ID: 24584352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.
    Guarini A; Marinelli M; Tavolaro S; Bellacchio E; Magliozzi M; Chiaretti S; De Propris MS; Peragine N; Santangelo S; Paoloni F; Nanni M; Del Giudice I; Mauro FR; Torrente I; Foà R
    Haematologica; 2012 Jan; 97(1):47-55. PubMed ID: 21993670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
    Lozanski G; Ruppert AS; Heerema NA; Lozanski A; Lucas DM; Gordon A; Gribben JG; Morrison VA; Rai KM; Marcucci G; Larson RA; Byrd JC
    Leuk Lymphoma; 2012 Sep; 53(9):1743-8. PubMed ID: 22369572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A unique lethal blastoid transformation of B-cell chronic lymphocytic leukemia carrying ATM/11q deletion and trisomy 12.
    Lu Y; Huang Q
    Leuk Res; 2009 Aug; 33(8):e124-6. PubMed ID: 19269030
    [No Abstract]   [Full Text] [Related]  

  • 14. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.
    Stankovic T; Stewart GS; Fegan C; Biggs P; Last J; Byrd PJ; Keenan RD; Moss PA; Taylor AM
    Blood; 2002 Jan; 99(1):300-9. PubMed ID: 11756185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.
    Stankovic T; Skowronska A
    Leuk Lymphoma; 2014 Jun; 55(6):1227-39. PubMed ID: 23906020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gene atm and chronic lymphocytic leukemia - review].
    Zhu DX; Xu W; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1242-6. PubMed ID: 18928637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion.
    Joshi AD; Dickinson JD; Hegde GV; Sanger WG; Armitage JO; Bierman PJ; Bociek RG; Devetten MP; Vose JM; Joshi SS
    Cancer Genet Cytogenet; 2007 Jan; 172(2):120-6. PubMed ID: 17213020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naïve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion.
    Lozano-Santos C; García-Vela JA; Pérez-Sanz N; Nova-Gurumeta S; Fernandez-Cuevas B; Gomez-Lozano N; Sánchez-Beato M; Sanchez-Godoy P; Bueno JL; Garcia-Marco JA
    Leuk Lymphoma; 2017 Apr; 58(4):859-865. PubMed ID: 27499002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.
    Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J
    Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
    Quijada-Álamo M; Hernández-Sánchez M; Alonso-Pérez V; Rodríguez-Vicente AE; García-Tuñón I; Martín-Izquierdo M; Hernández-Sánchez JM; Herrero AB; Bastida JM; San Segundo L; Gruber M; García JL; Yin S; Ten Hacken E; Benito R; Ordóñez JL; Wu CJ; Hernández-Rivas JM
    Leukemia; 2020 Jun; 34(6):1599-1612. PubMed ID: 31974435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.